MedTrace Logo

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-03-18

No results posted yet for this study

Summary

The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.

Conditions

Interventions

PROCEDURE

genetic analysis

genetic assay of blood sample drawn with patient's consent

PROCEDURE

genetic assay

genetic assay of blood sample drawn with patient's consent

Sponsors & Collaborators

Principal Investigators

  • Herbert Y Meltzer, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-11-30
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00178932 on ClinicalTrials.gov